[Please keep in mind the domain name of this site" ", or search in Baidu: Sanlian Literature Network]

The whole country mourned, which lasted for nearly half a month.

Half a month. The TV is basically a documentary that was only done before it was broadcast, such as a brief biography of the old chief, from his childhood to his later position as the top leader, and the ups and downs of the past few decades have flashed one by one in more than a dozen episodes of documentaries.

As a person who has a very close relationship with the old chief's family, Fan Wuxian naturally participated in the memorial activities held later, especially after following the leader of the Politburo, and laid a wreath as an important friend.

After a few months of dilution period, Fan Wuzhi and Donghai Province came up with a solution, bypassing the supervision of the central ministries and commissions, first of all, the research department of Haizhou Pharmaceutical Group was stripped out, and the Haizhou New Drug Research Institute was established, which was independently controlled by the government, and the R&D department of Haizhou Pharmaceutical Group was set up separately.

Later, Fan's Investment Group reached a cooperation intention with Donghai Province, and Fan's Investment Group injected 100 million yuan and obtained 80% of the equity of the research institute, thus becoming the new owner of this drug research and development institution with up to 500 people, mainly based on the framework of doctors and masters.

Because this case did not rise to the level of a direct acquisition of Haizhou Pharmaceutical Group, it bypassed the supervision scope of the central ministries and commissions, and waited until the forces that had previously opposed the acquisition of Haizhou Pharmaceutical Group by Fan's Investment Group came back to their senses. Moreover, in this matter, except for some criticism on the operation method, there is no suspicion of any violation, so the main body of Haizhou Pharmaceutical Group has not been moved, and Fan's Investment Group has only acquired a small part of the professional institutions that have been separated by the Donghai Provincial Government.

And this small-scale purchase price is also quite high, after all, the research institute not only has no profitability, but also needs to invest a lot of money every year to maintain its operation, which can be said to be a big burden for the entire Haizhou Pharmaceutical Group.

Prior to this, there were many people from Haizhou Pharmaceutical Group who said that the company had so many researchers, but they had never come up with any decent research results, but it was a large amount of research expenses and personnel expenses that dragged Haizhou Pharmaceutical Group to a crumbling and overwhelmed burden, so some people have long wanted to abolish the research department, and the representatives of the company have already had this proposal, but the group has not dared to take action, lest something big happen.

After all, in the past two years, because of the layoffs of enterprises, a lot of things have broken out that affect local stability, and at this time, from enterprise leaders to local leaders, they are generally reluctant to touch the interests of this area.

At this time, the leaders of Donghai Province, especially Wu Fukuan, the governor who was eager to get closer to the Fan family, immediately made a decision, respecting the opinions of the previous Haizhou Pharmaceutical Group, leaving the R&D department independent and taking the road of market-oriented operation.

However, Fan's Investment Group also said that with the continuous injection of new funds into the research institute. The Donghai provincial government's shareholding in the institute will also be diluted accordingly.

"In other words, if Fan's capital injection exceeds one billion, the Donghai provincial government's equity in the research institute will be less than two percent?" After Shen Ying learned the news, she asked Fan Wuxian, "It seems that you are determined to win this R&D department!" ”

"That's natural." Fan Wuxian nodded and replied, "In fact, what I really care about is the R&D team of this Haizhou Pharmaceutical Group, after all, the strength of this team is still very strong, but it is limited to the relationship between the system and has not played its due role. ”

There are a lot of good things in Fan Wuxi's hands, such as the secret recipe given to him by the teacher Fan Tianlan, these things can be commercialized to make them more conducive to the promotion of new drugs, but to turn traditional Chinese medicine preparations into tablets or capsules, oral liquids, etc., suitable for the current market demand, it is necessary to reposition, and make some pathological tests and toxicity analysis, or there are various test requirements that need to meet the requirements of the International Organization for Standardization. Finally, a result can be obtained that can allow the new drug to be marketed.

All this requires a professional R&D team to do. It's not that one or two people can do it.

Fan Wuxian seized the time to do the research and development and promotion of new drugs, mainly because he felt the huge pressure of European and American drugs, and wanted to make the domestic drug market fight a bloody way and regain many of the traditional drug markets that had been lost.

In recent years, it has been widely believed that the United States has overshadowed Europe in terms of drug research and development capabilities. However, according to the analysis of all the data in the past 20 years, in terms of drug innovation, the United States has not surpassed Europe in the R&D efficiency of new drugs, and the R&D capacity of European new drugs is still ahead of the United States, and compared with the newly developed new drugs, the clinical efficacy of most new drugs has not increased significantly.

Official and industry reports once generally believed that the United States had surpassed Europe in developing new drugs, but although the U.S. Congress and a large number of investors are encouraging pharmaceutical companies to develop and sell new drugs, these new drugs have no real value, and the efficacy of new drugs is only slightly higher than that of old drugs.

The U.S. is growing rapidly in global drug, first-in-class drug, biologics, and orphan drug development, but Europe's R&D capacity has barely decreased, and Europe remains a leader in developing all NCEs and global, high-margin NCEs. It is clear that the United States does not surpass Europe in the discovery of new compounds.

Drug R&D capabilities and total R&D investment are often confused, and a very typical propaganda is that the United States has developed itself into a major innovator in pharmaceuticals since the beginning of the 2000th century. This argument stems from the fact that the United States is investing more money in research and development, but it is still unknown how many genuine new inventions there are in American laboratories.

And the conclusion that the vast majority of new drugs are of high quality or important to patients is untenable by many responsible experts.

From the point of view of patients, physicians and health policy, quality means that a new drug is clinically more effective or has fewer side effects than existing medicines. However, many current surveys do not use data or treatment outcomes to assess the quality of new drugs. Some advertisements for new drugs clearly mislead consumers and claim that the new drugs are effective, but the efficacy of the two is almost the same in terms of the clinical manifestations of the patients who take the drugs.

In a nutshell. Commercial success often does not equate to significant improvements in efficacy.

For now, there is a real need to encourage companies to develop new drugs that are better than existing drugs, rather than developing drugs that are only slightly better than placebos. Therefore, some scholars have suggested that independent clinical trials sponsored by public institutions such as the National Institutes of Health in the United States can compare the advantages and risks with existing treatments, and that publicly-sponsored trials can also reduce costs and risks for manufacturers, and improve the R&D capabilities and competitiveness of small factories by reducing high-cost barriers.

"Now the government's approval of new drugs can be said to be completely liberalized, and there are no less than 20,000 new drugs on the market every year, but among them, there are not even 100 kinds of new drugs, and the rest are just some old drugs that are listed under new names after changing their packaging." When Fan Wuxian mentioned this problem, he said to Shen Ying, "For example, the medicines that often appear on TV commercials are actually very simple upgraded versions of cold powders, or simply the same thing has changed the packaging method, not only has not improved in terms of efficacy, or has been reduced, but the price is several times or dozens of times higher than the original product, which is very unfavorable for consumers who do not know the truth." ”

Fan Wuzhi is very clear that in view of the current problems such as insufficient attention, insufficient investment, and failure to keep up with basic research and development enterprises in domestic innovative drug research and development, it is impossible to change this situation by relying on the government, and only to do something by yourself.

It is necessary to rank among the world's advanced in the R&D and production of innovative drugs. First of all, it is necessary to cultivate a group of outstanding talents, including outstanding technical personnel and management personnel. Therefore, the first thing that should be solved is the incentive mechanism for scientific researchers engaged in the application of basic and development, and the issue of options and equity of scientists when intangible assets are shared, which mainly includes scientific research institutes and scientific researchers within enterprises.

After all, in order for the research and development of innovative drugs to eventually go to the market, in addition to the need for excellent technical talents, it is also necessary to create an excellent management team.

In addition to solving the problem of talents, it is necessary to strengthen basic research and lay a solid foundation for the successful research and development of innovative drugs. Governments in almost all developed countries spend most of their money on supporting basic research, while applied basic and development research is mainly funded by enterprises, and the same is true for the research and development of innovative drugs.

However, due to many reasons such as systems and mechanisms, it is difficult for state-owned and state-controlled enterprises that currently dominate to become the main body of innovation. In general. At present, the strength of such companies to spend huge sums of money on the research and development of original innovative drugs is still insufficient.

Therefore, at the present stage, it is necessary to push forward the achievements accumulated by various research institutes over the years to industrialization as soon as possible, and to set up some major special projects for industrialization to support them. With the universal and effective establishment of the modern enterprise system, the investment strength of a number of enterprises has increased, and enterprises will inevitably become the main body of scientific and technological innovation.

Now Fan Wuzhi is just taking this road out of advance, in order to enhance the research and development of domestic innovative drugs as soon as possible, so as not to lag behind foreign counterparts too much.

New technologies have become the starting point and an indispensable part of new drug research and development, and tracking cutting-edge key technologies is very important for the research and development of innovative drugs. According to the latest achievements of the human genome, it is a good idea to integrate high-tech drug research technologies such as molecular biology, structural biology, computer-aided virtual screening, combinatorial chemistry and high-throughput screening, and establish a platform for innovative drug discovery to be practiced in a variety of target protein systems related to important diseases.

In fact, the R&D of new drugs is also a set of systematic engineering, which guides the establishment of a high-tech platform for the centralized creation of new drugs, the formation of a research group composed of high-level interdisciplinary researchers, the improvement of the R&D system of innovative drugs, and the strengthening of the construction of key bottleneck technology platforms, such as preparation technology and pharmacokinetic platforms, which are not problems that can be solved by current state-owned enterprises.

After seeing that Fan's Investment Group does not seem to have much interest in acquiring Haizhou Pharmaceutical Group, the cadres and employees of Haizhou Pharmaceutical Group are very disappointed, after all, everyone is very clear about the current situation of Haizhou Pharmaceutical Group, and if we do not introduce strategic investors, I am afraid that it will soon be unable to hold on.

The so-called annual sales of more than 10 billion yuan and the like, just talk, at this time the group's profits have been declining, the debt ratio has been rising, if there is no breakthrough in the future, everyone will have to drink the northwest wind next year.

Previously, when Fan's Investment Group had the intention to acquire, as the employees of Haizhou Pharmaceutical Group, they were very willing, because everyone knew that the major enterprises acquired by Fan's now have a dominant living standard in the local area, and if Haizhou Pharmaceutical Group was successfully acquired by Fan's, there would be no exception.

But no one thought that this acquisition case would be stopped by the central ministries and commissions, and everyone's thoughts came to naught, which is really unacceptable. Seeing that the group's most unpopular R&D department gave another order, many people were happy, thinking that they had finally thrown out a big burden.

But Fan's Investment Group actually acquired the independent Haizhou New Drug Research Institute, which is a big surprise, compared to the new drug research institute that needs a lot of investment to support funds, the production enterprise can directly generate a part of the income.

Fan's ideas are always unpredictable.

However, after confirming through internal relations that Fan's is no longer interested in the acquisition of Haizhou Pharmaceutical Group, most of the employees of Haizhou Pharmaceutical Group feel a little angry, believing that the inaction of the central ministries and commissions has increased the risks they face, and if Haizhou Pharmaceutical Group collapses next year, won't they all be laid off?

Of course, leaders can get out in advance and serve in other places, but what way can they survive? As a skilled worker who has become professional, in fact, the lowest level of existence in this society, what kind of job can he find without the company he can work for?

Therefore, the employees of Haizhou Pharmaceutical Group organized a petition team of up to 200 people and went directly to the capital, of course, under the banner of a tour group.

There are no pop-ups